ARTICLE | Product Development
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence
December 4, 2024 1:31 AM UTC
Investors added over a billion dollars to Janux’s market cap on Tuesday, after updated Phase Ia data from its T cell engager therapy provided early validation for the hypothesis that conditionally active biologics can have impressive efficacy.
Janux Therapeutics Inc. (NASDAQ:JANX) reported that JANX007, which targets CD3 and PSMA, led to PSA declines of at least 50% in all 16 heavily pre-treated prostate cancer patients, when used pre-Pluvicto in the target dose range of 2-9 mg. In the subgroup, 63% achieved a 90% reduction in PSA, while 31% saw PSA levels drop by 99%…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654372/confidence-in-masked-t-cell-engagers-builds-with-janux-update